أعرض في EDS

Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice

التفاصيل البيبلوغرافية
العنوان: Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice
المؤلفون: Juan Suárez, Ana Luisa Gavito, Miguel Romero-Cuevas, Sergio Arrabal, Francisco Javier Pavón, Dolores Bautista, Elena Baixeras, Antonia Serrano, Juan Decara, Margarita Vida, Fernando Rodríguez de Fonseca
المساهمون: [Vida,M, Gavito,AL, Pavón,FJ, Serrano,A, Suarez,J, Arrabal,S, Decara,J, Romero-Cuevas,M, Rodríguez de Fonseca,F, Baixeras,E] Laboratorio de Investigación, IBIMA/Universidad de Málaga, Málaga, Spain. [Vida,M, Baixeras,E] Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y ́ Nutrición (CIBERobn), Instituto de Salud Carlos III (ISCIII) and Ministerio de Ciencia e Innovación (MICINN), Spain. [Vida,M, Suárez,J, Baixeras,E] Unidad de Gestión Clínica de Salud Mental, Hospital ́Universitario Regional de Málaga, Málaga, Spain. [Bautista,D] Unidad de Gestión Clínica de Anatomía Patológica, Hospital Universitario Regional de Málaga, Málaga, Spain., The present study was financially supported through funding from the Instituto de Salud Carlos III, Red de Trastornos Adictivos UE-FEDER 2012 (RD12/0028), Ministerio de Economía y Competitividad (PI13/02261), Plan Nacional sobre Drogas 049/2009 and 049/2013, Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE-FEDER (CTS-433), Consejería de Salud y Bienestar Social, Junta ́ Andalucía (TCMR0019, PI0552, PI0228-2013 and PI0823-2012). The I3SNS Program of the Andalusian 'Progreso y Salud' Foundation, Spain andthe National System of Health (Instituto de Salud Carlos III, grant number CP12/03109).
المصدر: Disease Models & Mechanisms, Vol 8, Iss 7, Pp 721-731 (2015)
Disease Models & Mechanisms
بيانات النشر: The Company of Biologists, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Male, Anatomy::Cells::Epithelial Cells::Hepatocytes::Hep G2 Cells [Medical Subject Headings], Acetil-CoA carboxilasa, Steatosis, Anatomy::Digestive System::Liver [Medical Subject Headings], Ratones, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-6 [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Oxygenases::Mixed Function Oxygenases::Fatty Acid Desaturases::Stearoyl-CoA Desaturase [Medical Subject Headings], Medicine (miscellaneous), lcsh:Medicine, Suppressor of Cytokine Signaling Proteins, AMP-Activated Protein Kinases, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Acyltransferases::Carnitine Acyltransferases::Carnitine O-Palmitoyltransferase [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::STAT Transcription Factors::STAT3 Transcription Factor [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Mice, chemistry.chemical_compound, Diseases::Digestive System Diseases::Liver Diseases::Fatty Liver::Non-alcoholic Fatty Liver Disease [Medical Subject Headings], Immunology and Microbiology (miscellaneous), AMP-activated protein kinase, Non-alcoholic Fatty Liver Disease, Organisms::Eukaryota::Animals [Medical Subject Headings], Phosphorylation, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Ligases::Carbon-Carbon Ligases::Acetyl-CoA Carboxylase [Medical Subject Headings], Phenomena and Processes::Metabolic Phenomena::Metabolism::Phosphorylation [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::Adaptor Proteins, Signal Transducing::Suppressor of Cytokine Signaling Proteins [Medical Subject Headings], Mice, Knockout, biology, Hígado, Fatty liver, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::AMP-Activated Protein Kinases [Medical Subject Headings], Hep G2 Cells, Recombinant Proteins, Carnitina O-palmitoiltransferasa, Fatty Acid Synthase, Type I, Fatty acid synthase, Citoquinesis, Organisms::Eukaryota::Animals::Animal Population Groups::Animals, Genetically Modified::Mice, Transgenic::Mice, Knockout [Medical Subject Headings], Liver, Lipogenesis, Supresor de proteínas señalizadoras de citocinas, Factor de transcripción STAT3, Cytokines, Stearoyl-CoA Desaturase, Fosforilación, Research Article, Ratones noqueados, lcsh:RB1-214, STAT3 Transcription Factor, medicine.medical_specialty, Phenomena and Processes::Metabolic Phenomena::Metabolism::Lipid Metabolism::Lipogenesis [Medical Subject Headings], Neuroscience (miscellaneous), Check Tags::Male [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Animal::Disease Models, Animal [Medical Subject Headings], Diet, High-Fat, Proteínas recombinantes, General Biochemistry, Genetics and Molecular Biology, Alimentación rica en grasa, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Recombinant Proteins [Medical Subject Headings], Interleucina-6, Carnitine palmitoyltransferase 1, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diet, High-Fat [Medical Subject Headings], Modelos de enfermedad en animales, Internal medicine, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Multifunctional Enzymes::Fatty Acid Synthase, Type I [Medical Subject Headings], medicine, lcsh:Pathology, Animals, Humans, Lipogénesis, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Cycle::Cell Division::Cytokinesis [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings], Carnitine O-Palmitoyltransferase, Fatty acid metabolism, Interleukin-6, lcsh:R, AMPK, Ratones consanguíneos C57BL, medicine.disease, Mice, Inbred C57BL, Disease Models, Animal, Endocrinology, chemistry, Suppressor of Cytokine Signaling 3 Protein, biology.protein, Estearoil-CoA desaturasa, Ácido graso sintasa tipo I, Organisms::Eukaryota::Animals::Animal Population Groups::Animals, Laboratory::Animals, Inbred Strains::Mice, Inbred Strains::Mice, Inbred C57BL [Medical Subject Headings], Células Hep G2, Esteatosis hepática no alcohólica, Acetyl-CoA Carboxylase
الوصف: Interleukin-6 (IL-6) has emerged as an important mediator of fatty acid metabolism with paradoxical effects in the liver. Administration of IL-6 has been reported to confer protection against steatosis, but plasma and tissue IL-6 concentrations are elevated in chronic liver diseases, including fatty liver diseases associated with obesity and alcoholic ingestion. In this study, we further investigated the role of IL-6 on steatosis induced through a high-fat diet (HFD) in wild-type (WT) and IL-6-deficient (IL-6−/−) mice. Additionally, HFD-fed IL-6−/− mice were also chronically treated with recombinant IL-6 (rIL-6). Obesity in WT mice fed a HFD associated with elevated serum IL-6 levels, fatty liver, upregulation of carnitine palmitoyltransferase 1 (CPT1) and signal transducer and activator of transcription-3 (STAT3), increased AMP kinase phosphorylation (p-AMPK), and downregulation of the hepatic lipogenic enzymes fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1). The HFD-fed IL-6−/− mice showed severe steatosis, no changes in CPT1 levels or AMPK activity, no increase in STAT3 amounts, inactivated STAT3, and marked downregulation of the expression of acetyl-CoA carboxylase (ACCα/β), FAS and SCD1. The IL-6 chronic replacement in HFD-fed IL-6−/− mice restored hepatic STAT3 and AMPK activation but also increased the expression of the lipogenic enzymes ACCα/β, FAS and SCD1. Furthermore, rIL-6 administration was associated with aggravated steatosis and elevated fat content in the liver. We conclude that, in the context of HFD-induced obesity, the administration of rIL-6 might contribute to the aggravation of fatty liver disease through increasing lipogenesis.
Summary: The administration of rIL-6 might contribute to the aggravation of fatty liver disease through increasing lipogenesis in HFD-induced obesity.
وصف الملف: application/pdf
اللغة: English
تدمد: 1754-8403
1754-8411
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311b02778dd0d4a225edf8548a97b7f6
http://dmm.biologists.org/content/8/7/721
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....311b02778dd0d4a225edf8548a97b7f6
قاعدة البيانات: OpenAIRE
الوصف
تدمد:17548403
17548411